Clinical Research

The Clinical Research Department of Regional Urology sets us apart from many urology practices. We participate in numerous clinical research projects with the major pharmaceutical companies both across the country and internationally. This research helps bring new medication to the market for use in the future. We also have been able to offer new forms of therapy to our patients that are not available.

When our patients participate in the clinical trials at Regional Urology, it gives them the opportunity to have medications and procedures that are unavailable to the general public. Patients receive test and study medications at no cost. Participation is always voluntary.

The research department at Regional Urology, LLC perform studies in the following areas:

  • Overactive Bladder Symptoms
  • Stress Incontinence
  • Urge Incontinence
  • BPH
  • Erectile Dysfunction
  • Low Testosterone
  • Prostate Cancer
  • Bladder Cancer
  • Prostatitis
  • Interstitial Cystitis/Bladder Pain

Study for Patients with Secondary Hyperoxaluria with Kidney Stones

The purpose of this study is to learn more about the effect of an investigational drug called ALLN-177. It is designed to break down oxalate when taken with food. Oxlate is an organic chemical that occurs naturally in many foods. Leafy plants such as spinach and rhubarb contain large amounts of oxalate. Oxalate is removed from the body by the kidneys and passed into the urine. Some people have too much oxalate in the urine, and this can cause kidney stones and other health problems.

If ALLN-177 is successful in breaking down oxalate in foods in the gut and decreasing the amount of oxalate absorbed, it may help treat these medical conditions. The study will enroll male and female patients 18 years or older who have a history of hyperoxaluria. The study will be conducted at approximately 12 to 18 research centers in the United States.

Non-Invasive Bladder Cancer Study

The purpose of this study is to gather information on the safety and effectiveness of the study drug, which is an investigational drug called apaziquone.

Apaziquone is an investigational, anti-cancer drug known as a bio-reductive alkylating indoloquinone which is thought to cause cell death. Early studies in humans have shown apaziquone has some anti-cancer activity that may prevent or delay the return of bladder cancer following surgery. It has been given to approximately 1314 people with bladder cancer in other research studies.

The standard of care for bladder tumors is to surgically remove the tumors via surgery (TURBT). The study is to determine if giving apaziquone right after the surgery will decrease the risk of the cancer coming back. Approximately 1869 people will be enrolled in this study. This study will take place in approximately 100 hospitals/institutions.

Bladder Control procedure in post-menopausal women that have Stress Urinary Incontinence (SUI)

The purpose of this clinical trial is to continue the evaluation of the performance of the Vesair® Bladder Control procedure in post-menopausal women that have Stress Urinary Incontinence (SUI). The VESICAL Clinical Trial will follow a carefully controlled protocol (a plan that details what researchers will do during the trial). As a clinical trial progresses, researchers report the results of the trial at scientific meetings, to medical journals and to various government agencies. Individual participants’ names will remain completely confdential and will not be mentioned in these reports. For more information about this study, visit: www.stopsui.com

* Required





CONTACT US

Request to be contacted for an appointment

Click Here